These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25165412)

  • 1. Effect of the Toll-like receptor 4 antagonist eritoran on retinochoroidal inflammatory damage in a rat model of endotoxin-induced inflammation.
    Ekici F; Karaca EE; Korkmaz S; Yüksel O; Gülbahar Ö; Alper M; Ercan S; Or M
    Mediators Inflamm; 2014; 2014():643525. PubMed ID: 25165412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eritoran attenuates tissue damage and inflammation in hemorrhagic shock/trauma.
    Korff S; Loughran P; Cai C; Lee YS; Scott M; Billiar TR
    J Surg Res; 2013 Oct; 184(2):e17-25. PubMed ID: 23777984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo Toll-like receptor 4 antagonism restores cardiac function during endotoxemia.
    Ehrentraut S; Lohner R; Schwederski M; Ehrentraut H; Boehm O; Noga S; Langhoff P; Baumgarten G; Meyer R; Knuefermann P
    Shock; 2011 Dec; 36(6):613-20. PubMed ID: 22089127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of eritoran tetrasodium, a toll-like receptor 4 antagonist, on intestinal microcirculation in endotoxemic rats.
    Yeh YC; Ko WJ; Chan KC; Fan SZ; Tsai JC; Cheng YJ; Sun WZ
    Shock; 2012 May; 37(5):556-61. PubMed ID: 22392144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury.
    Shimamoto A; Chong AJ; Yada M; Shomura S; Takayama H; Fleisig AJ; Agnew ML; Hampton CR; Rothnie CL; Spring DJ; Pohlman TH; Shimpo H; Verrier ED
    Circulation; 2006 Jul; 114(1 Suppl):I270-4. PubMed ID: 16820585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease in the inflammatory cytokines of LPS-stimulated PBMCs of patients with atherosclerosis by a TLR-4 antagonist in the co-culture with HUVECs.
    Talepoor AG; Rastegari B; Kalani M; Doroudchi M
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108295. PubMed ID: 34735917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of Toll-like receptor 4 inhibitor eritoran on renal ischemia-reperfusion injury.
    Liu M; Gu M; Xu D; Lv Q; Zhang W; Wu Y
    Transplant Proc; 2010 Jun; 42(5):1539-44. PubMed ID: 20620471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) signaling.
    Mcdonald KA; Huang H; Tohme S; Loughran P; Ferrero K; Billiar T; Tsung A
    Mol Med; 2015 Mar; 20(1):639-48. PubMed ID: 25375408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The toll-like receptor 4-antagonist eritoran reduces murine cardiac hypertrophy.
    Ehrentraut H; Weber C; Ehrentraut S; Schwederski M; Boehm O; Knuefermann P; Meyer R; Baumgarten G
    Eur J Heart Fail; 2011 Jun; 13(6):602-10. PubMed ID: 21613426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
    Opal SM; Laterre PF; Francois B; LaRosa SP; Angus DC; Mira JP; Wittebole X; Dugernier T; Perrotin D; Tidswell M; Jauregui L; Krell K; Pachl J; Takahashi T; Peckelsen C; Cordasco E; Chang CS; Oeyen S; Aikawa N; Maruyama T; Schein R; Kalil AC; Van Nuffelen M; Lynn M; Rossignol DP; Gogate J; Roberts MB; Wheeler JL; Vincent JL;
    JAMA; 2013 Mar; 309(11):1154-62. PubMed ID: 23512062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.
    Barochia A; Solomon S; Cui X; Natanson C; Eichacker PQ
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):479-94. PubMed ID: 21323610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deactivation of the lipopolysaccharide antagonist eritoran (E5564) by high-density lipoprotein-associated apolipoproteins.
    Fleischer JG; Rossignol D; Francis GA; Chan T; Lynn M; Wasan KM
    Innate Immun; 2012 Feb; 18(1):171-8. PubMed ID: 21382909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonism of lipopolysaccharide-induced blood pressure attenuation and vascular contractility.
    Ehrentraut S; Frede S; Stapel H; Mengden T; Grohé C; Fandrey J; Meyer R; Baumgarten G
    Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2170-6. PubMed ID: 17656666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of corneal inflammation by the TLR4 antagonist Eritoran tetrasodium (E5564).
    Sun Y; Pearlman E
    Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1247-54. PubMed ID: 18936141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TLR4 antagonist Eritoran protects mice from lethal influenza infection.
    Shirey KA; Lai W; Scott AJ; Lipsky M; Mistry P; Pletneva LM; Karp CL; McAlees J; Gioannini TL; Weiss J; Chen WH; Ernst RK; Rossignol DP; Gusovsky F; Blanco JC; Vogel SN
    Nature; 2013 May; 497(7450):498-502. PubMed ID: 23636320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid differentiation 2 as a therapeutic target of inflammatory disorders.
    Park SH; Kim ND; Jung JK; Lee CK; Han SB; Kim Y
    Pharmacol Ther; 2012 Mar; 133(3):291-8. PubMed ID: 22119168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis.
    Tidswell M; LaRosa SP
    Expert Rev Anti Infect Ther; 2011 May; 9(5):507-20. PubMed ID: 21609262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-like receptor 4/nuclear factor-kappa B pathway is involved in myocardial injury in a rat chronic stress model.
    Wang RP; Yao Q; Xiao YB; Zhu SB; Yang L; Feng JM; Li DZ; Li XL; Wu JJ; Chen J
    Stress; 2011 Sep; 14(5):567-75. PubMed ID: 21675862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of protective effects of apilarnil against lipopolysaccharide induced liver injury in rats via TLR 4/ HMGB-1/ NF-κB pathway.
    Doğanyiğit Z; Okan A; Kaymak E; Pandır D; Silici S
    Biomed Pharmacother; 2020 May; 125():109967. PubMed ID: 32018220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage effect of E5564, Toll-like receptor 4 antagonist on d-galactosamine and lipopolysaccharide-induced acute liver failure in rats.
    Kitazawa T; Tsujimoto T; Kawaratani H; Fukui H
    J Gastroenterol Hepatol; 2010 May; 25(5):1009-12. PubMed ID: 20546456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.